Buy Rating for Mediwound Driven by EscharEx’s Market Potential and Disruptive Role in Chronic Wound Care
Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Mediwound (MDWD – Research Report). The associated price target ...